Patent · US Active

AAV treatment of Huntington's disease

US11773392B2 · kind B2 · utility

0Cited by

22References

20Claims

0Family size

Assignee

University of Massachusetts · US

Inventors

Christian Mueller · Wiesbaden, DE
Neil Aronin · Newton, US
Edith Pfister · Boxborough, US

Key dates

Filing date	May 21, 2021
Grant date	Oct 3, 2023
Priority date	—
Expiry date	Dec 21, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14171
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.